ArticleEJHaem2024

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.

Stephen T Oh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.